La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Replimune Group Croissance future

Future contrôle des critères 2/6

Replimune Group devrait augmenter ses bénéfices et ses revenus de 26% et de 57.8% par an respectivement, tandis que le BPA devrait croître de croître de 31.9% par an.

Informations clés

23.6%

Taux de croissance des bénéfices

29.5%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.0%
Taux de croissance des recettes	58.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	27 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Replimune: Interesting Developer Of Oncolytic Immunotherapies

Dec 06

Replimune Group EPS misses by $0.02

Nov 05

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:REPL - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	104	-165	-186	N/A	4
3/31/2026	15	-226	-200	N/A	5
3/31/2025	2	-222	-181	-177	8
6/30/2024	N/A	-220	-193	-186	N/A
3/31/2024	N/A	-216	-191	-185	N/A
12/31/2023	N/A	-210	-176	-172	N/A
9/30/2023	N/A	-199	-157	-154	N/A
6/30/2023	N/A	-182	-145	-143	N/A
3/31/2023	N/A	-174	-130	-128	N/A
12/31/2022	N/A	-157	-121	-118	N/A
9/30/2022	N/A	-147	-111	-108	N/A
6/30/2022	N/A	-133	-100	-97	N/A
3/31/2022	N/A	-118	-85	-82	N/A
12/31/2021	N/A	-108	-78	-76	N/A
9/30/2021	N/A	-100	-72	-70	N/A
6/30/2021	N/A	-91	-66	-65	N/A
3/31/2021	N/A	-81	-64	-61	N/A
12/31/2020	N/A	-75	-59	-57	N/A
9/30/2020	N/A	-70	-66	-59	N/A
6/30/2020	N/A	-61	-69	-62	N/A
3/31/2020	N/A	-53	-67	-61	N/A
12/31/2019	N/A	-43	-62	-55	N/A
9/30/2019	N/A	-35	-49	-46	N/A
6/30/2019	N/A	-30	-35	-32	N/A
3/31/2019	N/A	-31	-28	-25	N/A
12/31/2018	N/A	-31	-24	-24	N/A
9/30/2018	N/A	-28	-20	-20	N/A
6/30/2018	N/A	-26	-18	-17	N/A
3/31/2018	N/A	-20	N/A	-16	N/A
12/31/2017	N/A	-17	N/A	-15	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: REPL devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: REPL devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: REPL devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de REPL ( 57.8% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de REPL ( 57.8% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de REPL devrait être élevé dans 3 ans

Replimune Group Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates decrease by 50%, EPS upgraded

Price target increased by 8.2% to US$14.67

Price target increased by 9.2% to US$14.56

Price target decreased by 64% to US$17.22

Consensus revenue estimates fall by 42%

No longer forecast to breakeven

Recent updates

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Chief Operating Officer notifies of intention to sell stock

Replimune: In The 'Buy Zone' Again

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Chief Medical Officer Andrea Pirzkall has left the company

Chief Business Officer exercised options and sold US$587k worth of stock

Chief Operating Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index